Inhalation OctOber 2022 33
OINDP expertise including
contract services
Proveris® Laboratories offers orally inhaled and nasal
drug product development (OINDP) expertise to
pharmaceutical developers, including contract services
employing new, innovative, in vitro techniques. ese
include measuring plume front velocity and evapora-
tion rate and quantifying deposition of inhaled drug
products using human-realistic models. Employing in
vitro approaches that are human-realistic can enable
companies to make data-driven decisions and expe-
dite product development and approval while saving
time and resources. Learn more about these tech-
niques and see data we have already published, avail-
able on the Proveris website at www.proveris.com/
scientific-posters.
Proveris Scientific Corporation
US: +1 505 460-8822
contactus@proveris.com
www.proveris.com
New spray drying capabilities
Particle engineering is being used increasingly in
drug development, particularly for complex dosage
forms such as orally inhaled and nasal drug prod-
ucts (OINDPs), where controlled deposition in the
respiratory system is key to efficacy. Particle engineer-
ing offers multiple options for tailoring particle size
to optimize and target delivery to a specific region.
It also offers a controlled manufacturing process to
build a stable, engineered product, which could pro-
vide significant advantages for the formulation of
biologics. Intertek has recently invested in spray dry-
ing to further our capabilities in the development of
respiratory products.
Intertek Pharmaceutical Services
UK: +44 1763 261648
bd.melbourn@intertek.com
www.intertek.com
Inhalationmag.com
Use the article archive FREE
with no registration required.
